MaxCyte Inc (MXCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MaxCyte Inc (MXCT) has a cash flow conversion efficiency ratio of -0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.46 Million) by net assets ($180.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MaxCyte Inc (MXCT) defensive interval to measure how many days the company can operate on defensive assets alone.
MaxCyte Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how MaxCyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MaxCyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MaxCyte Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cloud Air Co.Ltd
KQ:036170
|
0.001x |
|
Yong Pyong Resort Corp
KO:070960
|
0.006x |
|
LumenRadio AB
ST:LUMEN
|
0.034x |
|
Nexstim Oyj
HE:NXTMH
|
0.099x |
|
Fortune Information Systems Corp
TW:2468
|
0.088x |
|
LIG-ES SPAC
KQ:220260
|
0.025x |
|
Aspire Mining Ltd
AU:AKM
|
-0.036x |
|
Anixa Biosciences Inc
NASDAQ:ANIX
|
-0.132x |
Annual Cash Flow Conversion Efficiency for MaxCyte Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of MaxCyte Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of MaxCyte Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $206.25 Million | $-27.61 Million | -0.134x | -43.31% |
| 2023-12-31 | $232.17 Million | $-21.69 Million | -0.093x | -60.47% |
| 2022-12-31 | $253.97 Million | $-14.78 Million | -0.058x | -43.29% |
| 2021-12-31 | $262.90 Million | $-10.68 Million | -0.041x | +84.63% |
| 2020-12-31 | $33.23 Million | $-8.78 Million | -0.264x | +59.16% |
| 2019-12-31 | $13.60 Million | $-8.80 Million | -0.647x | +24.21% |
| 2018-12-31 | $12.28 Million | $-10.49 Million | -0.854x | -72.92% |
| 2017-12-31 | $19.60 Million | $-9.68 Million | -0.494x | -7.51% |
| 2016-12-31 | $5.08 Million | $-2.33 Million | -0.459x | -884.44% |
| 2015-12-31 | $-3.08 Million | $-180.50K | 0.059x | -94.99% |
| 2014-12-31 | $-1.65 Million | $-1.93 Million | 1.169x | +223.42% |
| 2013-12-31 | $-1.54 Million | $-557.80K | 0.361x | -89.96% |
| 2012-12-31 | $-590.70K | $-2.13 Million | 3.599x | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more